CDTX Cidara Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CDTX

Price (delayed)

$12.51

Market cap

$57.07M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.2

Enterprise value

$26.17M

Cidara Therapeutics Inc. isa is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company's portfolio is comprised of its ...

Highlights
The EPS has grown by 46% year-on-year and by 41% since the previous quarter
CDTX's equity is up by 43% year-on-year
The gross profit has grown by 11% from the previous quarter but it has contracted by 3.2% YoY
Cidara Therapeutics's quick ratio has decreased by 47% from the previous quarter and by 17% YoY
CDTX's debt is up by 12% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cidara.com
Peers: OMER ALKS AGEN ENZN

Key stats

What are the main financial stats of CDTX
Market
Shares outstanding
4.56M
Market cap
$57.07M
Enterprise value
$26.17M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.86
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.41
Earnings
Revenue
$63.91M
EBIT
-$22.49M
EBITDA
-$21.21M
Free cash flow
-$22.94M
Per share
EPS
-$5.2
Free cash flow per share
-$5.25
Book value per share
-$1.82
Revenue per share
$14.62
TBVPS
$15.33
Balance sheet
Total assets
$67.03M
Total liabilities
$75.24M
Debt
$4.88M
Equity
-$8.21M
Working capital
-$6.56M
Liquidity
Debt to equity
-0.59
Current ratio
0.9
Quick ratio
0.77
Net debt/EBITDA
1.46
Margins
EBITDA margin
-33.2%
Gross margin
97.6%
Net margin
-35.9%
Operating margin
-38.3%
Efficiency
Return on assets
-32.7%
Return on equity
-218%
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
-35.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CDTX stock price

How has the Cidara Therapeutics stock price performed over time
Intraday
-1.34%
1 week
-0.95%
1 month
1,091.43%
1 year
1,138.61%
YTD
1,483.54%
QTD
1,259.78%

Financial performance

How have Cidara Therapeutics's revenue and profit performed over time
Revenue
$63.91M
Gross profit
$62.38M
Operating income
-$24.48M
Net income
-$22.93M
Gross margin
97.6%
Net margin
-35.9%
CDTX's net margin is up by 41% QoQ and by 31% YoY
Cidara Therapeutics's operating margin has increased by 39% QoQ and by 26% YoY
CDTX's net income is up by 33% QoQ and by 32% YoY
Cidara Therapeutics's operating income has increased by 31% QoQ and by 27% YoY

Growth

What is Cidara Therapeutics's growth rate over time

Valuation

What is Cidara Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
0.86
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.41
The EPS has grown by 46% year-on-year and by 41% since the previous quarter
CDTX's equity is up by 43% year-on-year
CDTX's price to sales (P/S) is 75% lower than its 5-year quarterly average of 3.5 and 28% lower than its last 4 quarters average of 1.2
The company's revenue rose by 13% QoQ

Efficiency

How efficient is Cidara Therapeutics business performance
Cidara Therapeutics's return on assets has increased by 49% YoY and by 39% QoQ
Cidara Therapeutics's return on equity has increased by 44% QoQ
The return on sales has grown by 42% since the previous quarter and by 32% year-on-year

Dividends

What is CDTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CDTX.

Financial health

How did Cidara Therapeutics financials performed over time
The total assets is 11% less than the total liabilities
Cidara Therapeutics's quick ratio has decreased by 47% from the previous quarter and by 17% YoY
CDTX's current ratio is down by 44% since the previous quarter and by 17% year-on-year
CDTX's debt is 159% higher than its equity
CDTX's equity is up by 43% year-on-year
CDTX's debt is up by 12% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.